NCT01357811View on ClinicalTrials.gov

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Healthy Volunteer
Interventions
DRUG

eliglustat; digoxin

repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15

DRUG

digoxin

oral 0.25mg dose of digoxin (single dose) on Day 1

Trial Locations (1)

Unknown

PPD Phase I Clinic, Austin

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01357811 - A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults | Biotech Hunter | Biotech Hunter